These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 20964479)

  • 1. Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.
    Chaplin B; Eisen G; Idoko J; Onwujekwe D; Idigbe E; Adewole I; Gashau W; Meloni S; Sarr AD; Sankalé JL; Ekong E; Murphy RL; Kanki P
    AIDS Res Hum Retroviruses; 2011 Jan; 27(1):71-80. PubMed ID: 20964479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.
    Santoro MM; Alteri C; Ronga L; Flandre P; Fabeni L; Mercurio F; D'Arrigo R; Gori C; Palamara G; Bertoli A; Forbici F; Salpini R; Boumis E; Tozzi V; Visco-Comandini U; Zaccarelli M; Van Houtte M; Pattery T; Narciso P; Antinori A; Ceccherini-Silberstein F; Perno CF
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1285-93. PubMed ID: 22417570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria.
    Hawkins CA; Chaplin B; Idoko J; Ekong E; Adewole I; Gashau W; Murphy RL; Kanki P;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):228-34. PubMed ID: 19644383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
    Deletsu SD; Maina EK; Quaye O; Ampofo WK; Awandare GA; Bonney EY
    Medicine (Baltimore); 2020 Feb; 99(7):e18777. PubMed ID: 32049783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naïve patients in Burkina Faso.
    Tebit DM; Sangaré L; Tiba F; Saydou Y; Makamtse A; Somlare H; Bado G; Kouldiaty BG; Zabsonre I; Yameogo SL; Sathiandee K; Drabo JY; Kräusslich HG
    J Med Virol; 2009 Oct; 81(10):1691-701. PubMed ID: 19697403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and resistance mutations of non-B HIV-1 subtypes among immigrants in Southern Spain along the decade 2000-2010.
    de Felipe B; Pérez-Romero P; Abad-Fernández M; Fernandez-Cuenca F; Martinez-Fernandez FJ; Trastoy M; Mata Rdel C; López-Cortés LF; Leal M; Viciana P; Vallejo A
    Virol J; 2011 Aug; 8():416. PubMed ID: 21871090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006.
    Derache A; Maiga AI; Traore O; Akonde A; Cisse M; Jarrousse B; Koita V; Diarra B; Carcelain G; Barin F; Pizzocolo C; Pizarro L; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2008 Sep; 62(3):456-63. PubMed ID: 18556706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.
    Couto-Fernandez JC; Silva-de-Jesus C; Veloso VG; Rachid M; Gracie RS; Chequer-Fernandez SL; Oliveira SM; Arakaki-Sanchez D; Chequer PJ; Morgado MG
    Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):73-8. PubMed ID: 15867968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.
    Ibe S; Sugiura W
    Future Microbiol; 2011 Mar; 6(3):295-315. PubMed ID: 21449841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing subtypes and drug resistance mutations among HIV-1 infected children who failed antiretroviral therapy in Kelantan, Malaysia.
    Mohamad S; Deris ZZ; Yusoff NK; Ariffin TA; Shueb RH
    Braz J Infect Dis; 2012; 16(3):284-8. PubMed ID: 22729198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure.
    Lwembe R; Ochieng W; Panikulam A; Mongoina CO; Palakudy T; Koizumi Y; Kageyama S; Yamamoto N; Shioda T; Musoke R; Owens M; Songok EM; Okoth FA; Ichimura H
    J Med Virol; 2007 Jul; 79(7):865-72. PubMed ID: 17516531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.
    Pillay V; Pillay C; Kantor R; Venter F; Levin L; Morris L
    AIDS Res Hum Retroviruses; 2008 Nov; 24(11):1449-54. PubMed ID: 19000027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.
    Kolomeets AN; Varghese V; Lemey P; Bobkova MR; Shafer RW
    AIDS; 2014 Nov; 28(17):F1-8. PubMed ID: 25259833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.
    Lam EP; Moore CL; Gotuzzo E; Nwizu C; Kamarulzaman A; Chetchotisakd P; van Wyk J; Teppler H; Kumarasamy N; Molina JM; Emery S; Cooper DA; Boyd MA
    AIDS Res Hum Retroviruses; 2016 Sep; 32(9):841-50. PubMed ID: 27346600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response.
    Ojesina AI; Sankalé JL; Odaibo G; Langevin S; Meloni ST; Sarr AD; Olaleye D; Kanki PJ
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):770-9. PubMed ID: 16910833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
    Kityo C; Thompson J; Nankya I; Hoppe A; Ndashimye E; Warambwa C; Mambule I; van Oosterhout JJ; Wools-Kaloustian K; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS; Paton NI;
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):e45-e54. PubMed ID: 28129253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.
    Vergne L; Peeters M; Mpoudi-Ngole E; Bourgeois A; Liegeois F; Toure-Kane C; Mboup S; Mulanga-Kabeya C; Saman E; Jourdan J; Reynes J; Delaporte E
    J Clin Microbiol; 2000 Nov; 38(11):3919-25. PubMed ID: 11060045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.